InnoCure Therapeutics Inc.
June 16, 2025
Company Presentation
Oncology
InnoCure Therapeutics is a global biopharmaceutical company dedicated to the discovery and development of novel drugs based on next-generation Target Protein Degradation (TPD) mechanisms applicable to ‘undruggable’ targets for treating various cancers and rare diseases. We endeavor to develop novel drug candidates to address unmet medical needs and to commercialize our products in a global market by pursuing the collaboration model of out-licensing and co-development. The main pipelines in the modality of TPD (PROTAC), Molecular Glue, DAC (Degrader Antibody Conjugates) are as follows.
◈ ICTP-101 (targeted for c-MET) effective for NSCLC, GC, Solid tumors
◈ ICTP-201 (targeted for BRD4-NUT) effective for NMC, Blood cancers, c-Myc related Solid tumors
◈ ICTP-301 (targeted for SHP2) effective for Refractory solid tumors (CRC, Breast Cancer, NSCLC)
◈ ICTP-401 (target undisclosed) effective for Solid Tumors
◈ ICTP-501 / 601 (targets undisclosed) effective for Solid Tumors and Blood Cancers
.png)
Company HQ City:
Seongnam-si
Company HQ State:
Gyeonggi-do
Company HQ Country:
Korea, Republic of
Year Founded:
2018
Lead Product in Development:
Complete pre-clinical development result of a cMET-targeted oral degrader ICTP-101 for NSCLC will be available in August of 2025. IND for a global phase 1 study will be filed to US FDA, aiming for its approval to be granted by November, 2025.
ICTP-101 is being developed as 1) monotherapy for NSCLC patients with cMET amplification and overexpression and 2) combination therapy for NSCLC patients having resistance after MET-TKIs or EGFR-TKIs treatment.
The next lead product, ICTP-201 for rare disease NMC (NUT Midline Carcinoma) has its initiation plan of pre-clinical study in Q3, 2025.
CEO
Hye-Dong Yoo, PhD, CEO/Founder
Year Founded
2018
Development Phase of Lead Product
Pre-Clinical
Number of Unlicensed Products Looking for Licensing
6 products
◈ ICTP-101 (targeted for c-MET) for NSCLC, GC, Solid tumors
◈ ICTP-201 (targeted for BRD4-NUT) for NMC, Blood cancers, c-Myc related solid tumors
◈ ICTP-301 (targeted for SHP2) for Refractory solid tumors (CRC, Breast Cancer, NSCLC)
◈ ICTP-401 (molecular glue) for Solid tumors
◈ ICTP-501 / ICTP-601 (Degrader antibody conjugate) for Solid tumors / Blood cancers
Differential PROTAC development platforms as below.
◈ ELCBIL (E3 Ligase CRBN Binder Library) is a patentable CRBN Binder Library to protect PROTAC IP rights with improved efficiency and reinforce future PROTAC IP strategies which will place our company ahead of other competitors in relevant drug development sector.
◈ MILPROTAC (Minimizing Linker PROTAC) is a technology to improve oral absorption of PROTAC.
◈ MOGLUBIN (Molecular Glue Binder, Novel CRBN binder) acts to induce closer proximity between target protein & E3 ligase, leading to high affinity & PPI (protein-protein interaction) by overcoming the challenges associated with IMiD scaffolds and providing wide scalability of drug targets.
◈DAC (Degrader Antibody Conjugate) is a new modality expanded from ADC (Antibody Drug Conjugate) and acts to help selective entry into target cells, leading to more effective degradation of target proteins with approximately 250-times more cytotoxicity.
When you expect your next catalyst update?
- Completion of GLP Tox Study (ICTP-101)
- FDA IND filing and Approval (ICTP-101)
What is your next catalyst (value inflection) update?
August 2025, November 2025
Website
http://innocurethera.com/
Primary Speaker
)
)
)
)
){kind=logo}
)
){kind=logo}